Edgewise Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
Edgewise Therapeutics, Inc. (EWTX) reported Other Comprehensive Income (Loss), Net of Tax of -$248.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$248.00K.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$929.00K.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $497.00K, a 76.39% decline year-over-year.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was -$197.00K.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2025 was $257.00K, a 19.94% decline from fiscal 2024.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2024 was $321.00K, a 77.92% decline from fiscal 2023.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2023 was $1.45M.
- Edgewise Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2022 was -$841.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$248.00K 10-Q · filed 2026-08-06 | -$1.18M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$929.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $257.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $497.00K 10-Q · filed 2025-11-06 | $300.00K derived: sum of 2 quarters · filed 2026-08-06 | $281.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$197.00K 10-Q · filed 2026-08-06 | -$216.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$19.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $321.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $2.10M 10-Q · filed 2025-11-06 | $1.91M derived: sum of 2 quarters · filed 2025-11-06 | $952.00K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$193.00K 10-Q · filed 2025-11-06 | -$1.15M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | -$960.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $1.45M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $123.00K 10-Q · filed 2024-11-07 | -$173.00K derived: sum of 2 quarters · filed 2024-11-07 | $931.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$296.00K 10-Q · filed 2024-11-07 | $808.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.10M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$841.00K 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $157.00K 10-Q · filed 2023-11-09 | -$247.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.67M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$404.00K 10-Q · filed 2023-11-09 | -$1.82M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$1.42M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | -$514.00K 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $9.00K 10-Q · filed 2022-11-03 | $30.00K derived: sum of 2 quarters · filed 2022-11-03 | -$24.00K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $21.00K 10-Q · filed 2022-11-03 | -$33.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$54.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |